Redsense Medical Announces Pilot Study in Berlin
Redsense Medical AB partners with a leading dialysis provider for a pivotal pilot study in Berlin.
Sammanfattning
Redsense Medical AB is set to conduct a pilot study in Berlin, evaluating their Blood Leakage Alarm system in collaboration with a leading dialysis care provider.
In a significant move, Redsense Medical AB has announced a pilot study in collaboration with one of Europe's leading dialysis care providers. This study, set to commence in December 2025 at a partner clinic in Berlin, represents a crucial step in evaluating the Redsense Blood Leakage Alarm system's performance in a real-world clinical environment.
The partnership with a major operator in the European dialysis market underscores Redsense's commitment to enhancing clinical evidence for its innovative solutions. CEO Sebastien Bollue emphasized the importance of this collaboration, stating, 'This pilot will give us valuable, up-to-date clinical data and further insight into the integration of our technology in everyday dialysis practice.'
Scheduled to run through the first half of 2026, the study will involve approximately 150-200 hemodialysis treatments. The Redsense systems will be provided on a loan basis, allowing the clinic to assess usability, risk reduction, and workflow integration comprehensively.
The anticipated scientific publication from this study will bolster Redsense's clinical validation efforts and support the broader adoption of its technology across the European market. This aligns with the company's strategy to expand its footprint and set new standards in hemodialysis care.
From an investment perspective, this development could be seen as a positive signal for Redsense Medical. The collaboration with a prominent dialysis provider not only validates the potential of their technology but also opens doors to new market opportunities. Investors might consider this an opportune moment to 'buy' into Redsense, given the potential for growth and increased market presence.
Källa
Sammanfattning
Redsense Medical AB, baserat i Halmstad, Sverige, meddelar att de kommer att genomföra en pilotstudie i samarbete med en ledande global leverantör av dialysvård vid en partnerklinik i Berlin, Tyskland, med start i december 2025. Studien syftar till att utvärdera Redsense Blood Leakage Alarm-systemet i en verklig klinisk miljö och samla in data om användbarhet, riskreduktion av blodläckage och integration i arbetsflödet. Samarbetet med en av Europas största dialysleverantörer är ett viktigt steg för att stärka den kliniska bevisbasen för Redsense lösning och utöka företagets närvaro i Europa. Studien kommer att genomföras under första halvåret 2026 och involvera 150-200 hemodialysbehandlingar. Resultaten förväntas leda till en vetenskaplig publikation som stödjer fortsatt klinisk validering och rekommendation av Redsense teknik på den europeiska marknaden.
